港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批

智通财经06-26

智通财经APP获悉，君实生物(01877)涨超3%，截至发稿，涨3.07%，报11.42港元，成交额299.53万港元。消息面上，君实生物宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗(商品名：拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得国家药监局（NMPA）批准。这是特瑞普利单抗在内地获批的第十项适应症。天风证券此前...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446381270?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-26 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446381270","market":"sh","top_or_hot":-1,"title":"港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，君实生物(01877)涨超3%，截至发稿，涨3.07%，报11.42港元，成交额299.53万港元。消息面上，君实生物宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗(商品名：拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得国家药监局（NMPA）批准。这是特瑞普利单抗在内地获批的第十项适应症。天风证券此前...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1140606.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-26 10:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1140606.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，君实生物(01877)涨超3%，截至发稿，涨3.07%，报11.42港元，成交额299.53万港元。消息面上，君实生物宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗(商品名：拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得国家药监局（NMPA）批准。这是特瑞普利单抗在内地获批的第十项适应症。天风证券此前...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1140606.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688180","symbol_name":"君实生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1140606.html","article_id":"2446381270","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446381270","pubTimestamp":1719369574,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，君实生物宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得国家药监局批准。这是特瑞普利单抗在内地获批的第十项适应症。天风证券此前指出，公司营业收入增长主要来自商业化药品销售收入的增长，其中核心产品特瑞普利单抗贡献突出。2023 年，特瑞普利单抗销售收入9.19 亿元，同比增长约24.93%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","07226":"XL二南方恒科","HSTECH":"恒生科技指数","BK1583":"高瓴概念","HSCEI":"国企指数","BK1515":"抗疫概念","01877":"君实生物","BK0239":"医药制造","YANG":"三倍做空富时中国ETF-Direxion","BK1161":"生物科技"},"translate_title":"Hong Kong stocks changed Junshi Biotech (01877) rose more than 3% toripalimab triple-negative breast cancer indication approved in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1,"07226":1,"HSCEI":1,"HSTECH":1,"YANG":1},"content_text":"智通财经APP获悉，君实生物(01877)涨超3%，截至发稿，涨3.07%，报11.42港元，成交额299.53万港元。消息面上，君实生物宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗(商品名：拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得国家药监局（NMPA）批准。这是特瑞普利单抗在内地获批的第十项适应症。天风证券此前指出，公司营业收入增长主要来自商业化药品销售收入的增长，其中核心产品特瑞普利单抗贡献突出。2023 年，特瑞普利单抗销售收入9.19 亿元，同比增长约24.93%。2024 年第一季度于国内市场实现销售收入约3.07 亿元，同比增长约56.82%。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446381270"}